Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.75), $0.06 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $7.23 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.